Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CKS1B | P61024 | 1/20 | 0.52 |
| ▸ | SKP1 | P63208 | 1/20 | 0.52 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29848257 | 1.00 | MAPT (0.68) | MAPTALDH1A1LMNAKDM4EMAPK1 | |
| SCHEMBL3206557 | 0.96 | ALDH1A1 (0.63) | MAPTALDH1A1LMNAKDM4EMAPK1 | |
| SCHEMBL23612210 | 0.94 | MAPT (0.60) | MAPTALDH1A1LMNAKDM4EMAPK1 | |
| SCHEMBL23612250 | 0.94 | MAPT (0.60) | MAPTALDH1A1LMNAKDM4EMAPK1 | |
| SCHEMBL10151470 | 0.91 | MAPT (0.58) | MAPTALDH1A1LMNAKDM4EMAPK1 | |
| SCHEMBL31039903 | 0.90 | MAPT (0.56) | MAPTALDH1A1LMNAKDM4EMAPK1 | |
| SCHEMBL23783356 | 0.90 | GPR119 (0.65) | MAPTALDH1A1LMNAKDM4EMAPK1 | |
| SCHEMBL17925102 | 0.86 | MAPT (0.54) | MAPTALDH1A1LMNAKDM4EMAPK1 | |
| SCHEMBL596003 | 0.84 | MAPT (0.65) | MAPTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL26436117 | 0.84 | MAPT (0.51) | MAPTALDH1A1LMNAKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-3641762-B1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-12521440-B2 | Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | BEONE MEDICINES I GMBH (CH) | 2026-01-13 | — | — | US | disclosed |
| US-12454521-B2 | Targeted protein degradation | C4 THERAPEUTICS, INC. | 2025-10-28 | — | — | US | disclosed |
| US-12441740-B2 | N/O-linked degrons and degronimers for protein degradation | C4 THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250205345-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE SWITZERLAND GMBH (CH) | 2025-06-26 | — | — | US | disclosed |
| EP-1718645-A1 | 2-(PYRIDIN-3-YLAMINO)-PYRIDO 2,3-D PYRIMIDIN-7-ONES | Warner-Lambert Company LLC (US) | 2006-11-08 | — | — | EP | disclosed |
| US-20060199802-A1 | Pyridyl derivatives and their use as therapeutic agents | DISCOVERY PARTNERS INTERNATIONAL, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2005082903-A1 | 2-(PYRIDIN-3-YLAMINO)-PYRIDO[2,3-D]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050182078-A1 | 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones | WARNER-LAMBERT COMPANY, LLC | 2005-08-18 | — | — | US | disclosed |
| US-20050096343-A1 | Dual action antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2005-05-05 | — | — | US | disclosed |
| EP-1432705-A2 | DUAL ACTION ANTIBIOTICS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003032962-A2 | DUAL ACTION ANTIBIOTICS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003031443-A1 | DUAL ACTIONS ANTIBIOTICS COMPRISING A OXAZOLDINONE AND A QUINOLONE OR NAPHTHYRIDINONE MOIETY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003031441-A1 | MULTIPLE ACTION COMPOUNDS | MORPHOCHEN AKTIENGESELLSCHAFT FÜR KOMBINATORISCHE CHEMIE (DE) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441740-B2 | N/O-linked degrons and degronimers for protein degradation | CRBN, CBL, STUB1 | MAPT 3822/4885ALDH1A1 4548/4885LMNA 1209/4885 |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | PSMC3, PSMA6, ADRM1 | MAPT 2902/4885ALDH1A1 3269/4885LMNA 3472/4885 |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBLC, CBL | MAPT 4527/4885ALDH1A1 4035/4885LMNA 921/4885 |
| US-12454521-B2 | Targeted protein degradation | STUB1, MDM2, UBE3A | MAPT 288/4885ALDH1A1 2966/4885LMNA 3552/4885 |
| US-20050096343-A1 | Dual action antibiotics | SLC11A2, MRPL21, MAP2K5 | MAPT 4706/4885ALDH1A1 2592/4885LMNA 3271/4885 |
| US-20250205345-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | MAPT 3793/4885ALDH1A1 4351/4885LMNA 3914/4885 |
| US-20050182078-A1 | 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones | CDK2, CDK4, CDK1 | MAPT 4002/4885ALDH1A1 1787/4885LMNA 945/4885 |
| US-20060199802-A1 | Pyridyl derivatives and their use as therapeutic agents | PYCR1, PNPO, UQCRC1 | MAPT 3990/4885ALDH1A1 2728/4885LMNA 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.